The rate of young women dying from cervical cancer in the United Kingdom has significantly decreased following the widespread implementation of the Human Papillomavirus (HPV) vaccine, according to new research. A study analyzing mortality data from England between 2001 and 2024 found that among women aged 20-24 who received the vaccine, no deaths from cervical cancer occurred, a stark contrast to the approximately 23 expected deaths in the most recent five-year period analyzed.
This groundbreaking study, published in The Lancet and led by researchers at Queen Mary University of London, suggests an estimated 100% reduction in deaths from the disease in this age group. For earlier cohorts who were offered vaccination up to age 18, death rates from cervical cancer fell by approximately 80% in the 20-24 age bracket. The research also indicated a near two-thirds reduction in mortality rates for women aged 30-34.
Impact of Vaccination on Cervical Cancer
Human papillomavirus (HPV) is the cause of about 95% of cervical cancers. The HPV vaccine is recommended in the UK for girls aged 12-13 and individuals at higher risk from HPV infection. Researchers estimate that the vaccine has already prevented around 200 cervical cancer deaths in England, with this number projected to increase substantially as more individuals are vaccinated.
Professor Peter Sasieni, the study's lead author, stated that for over two decades, his team has gathered evidence demonstrating that HPV causes cervical cancer and that vaccination prevents infections, precancerous changes, and the disease itself. He emphasized the vaccine's remarkable ability to almost eliminate certain types of cancer and the critical importance of maintaining high vaccination levels to ensure broad protection.
Global Goals and Current Uptake
The World Health Organization (WHO) has set a global strategy aiming to eliminate cervical cancer, with a target for all countries to vaccinate 90% of girls by age 15 by 2030. This initiative also includes screening 70% of women and treating 90% of those with cervical disease. Projections suggest these efforts could prevent 62 million deaths and 74 million new cases of cervical cancer globally by 2120.
However, uptake of the HPV vaccine in the UK remains a concern, falling short of the 90% target needed to eliminate cervical cancer as a public health issue. Current vaccination rates among girls aged 15 are between 76% and 86%. This decline in vaccination rates, alongside falling cervical screening rates, contributes to the approximately 685 cervical cancer deaths that occur annually in England alone.
Call for Increased Vaccination
Cancer Research UK, a key contributor to the vaccine's development, highlighted the findings as a significant milestone. Michelle Mitchell, chief executive of the charity, stated that the research provides concrete evidence of the vaccine saving lives and demonstrates the power of combining scientific advancement with robust public health programs. She noted that a future with very few cervical cancer cases is now visible but is at risk due to declining vaccine uptake.
Mitchell urged the UK government and health systems to take targeted action to reach communities with lower vaccination rates. Caroline Temmink, director of vaccination at the NHS, expressed excitement about the vaccine's potential to protect an entire generation from cervical cancer and other HPV-related cancers. She confirmed that alongside cervical screening, HPV vaccination is central to the NHS's ambition to eliminate cervical cancer by 2040, urging eligible individuals to accept the vaccination offer.